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Background: It was recently reported that iron oxide nanoparticles attenuated antigen-specific 
humoral responses and T cell cytokine expression in ovalbumin-sensitized mice. It is pres-
ently unclear whether iron oxide nanoparticles influence T helper 1 cell-mediated immunity. 
The present study aimed to investigate the effect of iron oxide nanoparticles on delayed-type 
hypersensitivity (DTH), whose pathophysiology requires the participation of T helper 1 cells 
and macrophages.
Methods: DTH was elicited by a subcutaneous challenge with ovalbumin to the footpads of 
mice sensitized with ovalbumin. Iron oxide nanoparticles (0.2–10 mg iron/kg) were admin-
istered intravenously 1 hour prior to ovalbumin sensitization. Local inflammatory responses 
were examined by footpad swelling and histological analysis. The expression of cytokines by 
splenocytes was measured by enzyme-linked immunosorbent assay.
Results: Administration of iron oxide nanoparticles, in a dose-dependent fashion, significantly 
attenuated inflammatory reactions associated with DTH, including the footpad swelling, the 
infiltration of T cells and macrophages, and the expression of interferon-γ, interleukin-6, and 
tumor necrosis factor-α in the inflammatory site. Iron oxide nanoparticles also demonstrated a 
suppressive effect on ovalbumin-stimulated production of interferon-γ by splenocytes and the 
phagocytic activity of splenic CD11b+ cells.
Conclusion: These results demonstrated that a single dose of iron oxide nanoparticles attenu-
ated DTH reactions by suppressing the infiltration and functional activity of T helper 1 cells 
and macrophages in response to antigen stimulation.
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Introduction
Engineered nanoparticles have been increasingly applied in many fields, including 
photonics, catalysis, magnetics, and biomedical applications. Among various nano-
materials, iron oxide nanoparticles possess a unique property of superparamagnetism 
that confers advantages for biomedical applications, including the generation of heat 
in alternating magnetic fields, and an ability to guide specific targeting by an external 
magnetic field. This property plays a central role in the development of iron oxide 
nanoparticles for contrast enhancement, targeted delivery of drugs or genes, tissue 
engineering, cancer thermal therapy, magnetic transfection, chelation therapy, and 
tissue engineering.1–7 Given the widespread potential applications of iron oxide nano-
particles and their impending commercialization, exposure of humans and animals to 
iron oxide nanoparticles is likely to increase significantly in the near future. Therefore, 
evaluation of the health impact of iron oxide nanoparticles is important.
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Medicinal preparations of superparamagnetic iron 
oxide nanoparticles have been used as diagnostic contrast-
ing agents for magnetic resonance imaging of focal liver 
lesions.7–10 It has been well documented that systemically 
administered iron oxide nanoparticles are rapidly engulfed 
by the reticuloendothelial system, with the spleen being 
one of the major organs for particle distribution.7,11,12 
Accordingly, the impact of iron oxide nanoparticles on 
the functionality of immune cells has become a focus 
of research. Exposure of primary macrophages to iron 
oxide nanoparticles results in a marked induction of 
oxidative stress and apoptosis.13 In addition, iron oxide 
nanoparticles suppress the phagocytic activity of RAW 
264.7 cells – a murine macrophage line – and increase 
the production of tumor necrosis factor-α (TNF-α) and 
nitric oxide.14 Murine studies have also demonstrated that 
intratracheal instillation of iron oxide nanoparticles elicits 
proinflammatory and prooxidative effects, as evidenced 
by a marked infiltration of inflammatory cells in lung tis-
sues and a diminished level of intracellular glutathione in 
bronchoalveolar lavage cells.15 In addition to macrophages, 
T cells are also a sensitive target in the immune system to 
iron oxide nanoparticles. Oral and intravenous administra-
tions of iron oxide nanoparticles alter T cell cellularity in 
normal nonsensitized mice.16,17 It has been reported that 
serum levels of interleukin-2 (IL-2), IL-10, and interferon-γ 
(IFN-γ) are elevated in mice intravenously administered 
with iron oxide nanoparticles.16 Moreover, it was recently 
reported that exposure to iron oxide nano  particles 
suppresses humoral immunity and influences antigen-
specific T cell reactivity.18,19 Collectively, these results 
clearly demonstrate that the functionality of macrophages 
and T cells is modulated by iron oxide nanoparticles upon 
in vitro and in vivo exposure.
A previous study showed that both T helper 1 (Th1)- and 
Th2-type immune responses are suppressed by iron oxide 
nanoparticle administration, in which Th2 cells appear less 
sensitive.19 Moreover, direct exposure of ovalbumin-primed 
splenocytes to iron oxide nanoparticles primarily inhibits 
antigen-specific Th1 cytokine expression.18 On the basis of 
these results, it was hypothesized that iron oxide nanopar-
ticles may modulate Th1 cell-mediated immune responses. 
A murine model of delayed-type hypersensitivity (DTH), 
whose pathophysiology requires the functions of antigen-
activated Th1 cells and macrophages,20 was employed to 
investigate the effect of iron oxide nanoparticles on Th1 
cell-mediated immunity.
Materials and methods
Reagents and chemicals
All reagents were purchased from Sigma-Aldrich Corpora-
tion (St Louis, MO) unless otherwise stated. Enzyme-linked 
immunosorbent assay sets for cytokine measurement were 
purchased from BD Biosciences (San Jose, CA). Cell culture 
supplies were obtained from Thermo Scientific HyClone 
(Logan, UT). Resovist® (Bayer Schering Pharma AG, Berlin, 
Germany) – a commercial preparation of carboxydextran-
coated iron oxide nanoparticles containing 28 mg iron/mL 
– was used in the present study. The iron oxide nanoparticles 
of Resovist exhibited a monodisperse population of particles 
with an average diameter of 58.7 nm, as measured using a 
particle size analyzer (Zetasizer Nano-S, Malvern Instru-
ments Ltd, Malvern, Worcestershire, UK).18 The crystalline 
core of ferucarbotran (Resovist) is composed of magnetite 
(Fe3O4) and maghemite (γ-Fe2O3).7
Protocol of animal experiments
Male BALB/c mice (5–6 weeks old) were purchased 
from the Animal Breeding Center of the National Taiwan 
University Hospital (Taipei, Taiwan). On arrival, the mice 
were randomized, transferred to plastic cages containing a 
sawdust bedding (five mice per cage), and quarantined for 
at least 1 week. The mice were given standard laboratory 
food and water ad libitum. The mice were randomly 
divided into the following groups (five mice per group; 
Figure 1): (1) nonsensitized (but ovalbumin-challenged) 
group; (2) untreated ovalbumin-sensitized and challenged 
group; (3) vehicle-treated plus ovalbumin-sensitized and 
challenged group; and (4) iron oxide nanoparticle-treated 
plus ovalbumin-sensitized and challenged group. A single 
dose of iron oxide nanoparticles (0.2–10 mg iron/kg; 0.2 mL/
mouse) and/or vehicle (saline) were administered to mice via 
Day 0
Treatment
1 h
OVA
sensitization
OVA
challenge Sacrifice
8 7
Figure  1  Protocol  of  iron  oxide  nanoparticle  administration  and  ovalbumin 
sensitization and challenge. BALB/c mice were randomly divided into the following 
groups (five mice per group): (1) nonsensitized (but ovalbumin-challenged) group; 
(2) untreated ovalbumin-sensitized and challenged group; (3) vehicle-treated (saline 
0.2 mL/mouse) plus ovalbumin-sensitized and challenged group; and (4) iron oxide 
nanoparticle-treated (0.2–10 mg iron/kg, 0.2 mL/mouse) plus ovalbumin-sensitized and 
challenged group. The dosing regimen for iron oxide nanoparticle administration and 
antigen sensitization and challenge are described in the materials and methods.
Abbreviation: OVA, ovalbumin.
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the tail vein 1 hour prior to ovalbumin sensitization on day 
zero. Except for the nonsensitized group, each mouse was 
sensitized with ovalbumin by a subcutaneous injection using 
0.1 mL sensitization solution (100 µg ovalbumin and 1 mg 
alum in saline). The hind footpads of all mice were challenged 
subcutaneously with 20 µL of 10 µg ovalbumin in saline 
on day seven. DTH reactions represented by the degree of 
footpad swelling were measured using an electronic caliper, 
Model No. 4120 (King Life Technology Company Ltd, Taipei, 
Taiwan) before and 24 hours after the ovalbumin challenge. 
The paw swelling was determined as the following:
  Footpad swelling (mm) = Footpad thickness after    
  ovalbumin challenge − Footpad thickness before  
    ovalbumin challenge.
The mice were then sacrificed, and their serum 
samples, spleens, and footpads were harvested for further 
measurements. All animal experiments were approved by 
the   Institutional Animal Care and Use Committee of the 
National Taiwan University.
Histological analysis of footpads
The footpads of mice were fixed with 10% neutral buffered 
formalin for 1 day followed by decalcification for 2 days. 
The tissue specimens were embedded in paraffin, cut into 
3–4 µm sections, and stained with hematoxylin and eosin 
for routine histopathology.
Immunohistochemical staining
The tissue sections were deparaffinized and then rehydrated 
following a standard procedure. The rehydrated slides were 
immersed in Trilogy™ (Cell Marque, Hot Springs, AR) at 
121°C for 15 minutes for antigen retrieval. The endogenous 
peroxidase activity was then quenched with 3% hydrogen 
peroxide in methanol and blocked with normal horse serum. 
Antimouse CD3, F4/80, Foxp3, IFN-γ, IL-6, or TNF-α mono-
clonal antibodies were applied onto each section overnight. 
The slides were treated with super enhancer and then incu-
bated with polyhorseradish peroxidase reagent. For visual-
ization, the slides were treated with the peroxidase substrate 
3-amino-9-ethylcarbazole followed by hematoxylin counter 
staining (blue color). The number of positive cells showing 
dark-red color was counted manually.
Splenocyte cultures and measurement  
of splenocyte viability
Spleens from the mice of the same group were aseptically 
isolated, pooled, and made into single cell suspensions 
as described previously.19 The viability of splenocytes 
was determined by the 3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyl-tetrazolium bromide (methylthiazol tetrazolium) 
assay described previously.21 Splenocytes (5 × 106 cells/mL) 
were seeded into 96-well plates. The cells were either left 
unstimulated or stimulated with ovalbumin for 68 hours. 
A methylthiazol tetrazolium stock solution (5 mg/mL in phos-
phate buffered saline) was then added to each well (10 µL/
well) and incubated for 4 hours. The formed formazan was 
dissolved with 0.1 N acid-isopropanol (100 µL/well); the 
optical density was measured at 570 nm (and at 630 nm as a 
background reference) using a microplate reader (Dynatech 
Laboratories Inc, Chantilly, VA).
Measurement of cytokines by enzyme-
linked immunosorbent assay
Splenocytes (5 × 106 cells/mL) were cultured in 48-well 
plates (250 µL/well) followed by stimulation with ovalbumin 
(50 µg/mL) for 72 hours. The supernatants were harvested 
and quantified for IL-4 and IFN-γ by enzyme-linked immu-
nosorbent assay.22
Measurement of the phagocytic activity 
of splenic CD11b+ cells
Splenic CD11b+ cells were isolated using a commercial 
kit (BD IMag™ Cell Separation System; BD Biosciences) 
following the supplier’s protocol. The purity of isolated 
cells was confirmed to be $90% by flow cytometry 
(FACSCalibur™; BD Biosciences) using a fluorescein 
isothiocyanate-conjugated antimouse CD11b monoclonal 
antibody (clone M1/70; BD Biosciences). The phagocytic 
activity of the splenic CD11b+ cells was measured using 
pH-sensitive pHrodo® Escherichia coli BioParticles™ 
conjugate (Invitrogen Life Technologies, Carlsbad, CA) 
following the manufacturer’s instructions. In brief, the 
CD11b+ cells (5 × 105 cells/mL) were seeded into 96-well 
plates (0.1 mL/well) and cocultured with pHrodo E. coli 
BioParticles conjugate for 3 hours. After washing, cells were 
collected, and the single cell fluorescence of 5000 cells for 
each sample was measured at emission of 575 nm using a 
FACSCalibur flow cytometer.
Statistical analysis
The mean ± standard error was determined for each treatment 
group in the individual experiments. Homogeneous data were 
then evaluated by a parametric analysis of variance, and 
Dunnett’s two-tailed t-test was used to compare the results 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2731
Effect of iron oxide nanoparticles on delayed-type hypersensitivityInternational Journal of Nanomedicine 2012:7
for the treatment groups with those of the control group. 
P , 0.05 was defined as statistical significance.
Results
Administration of iron oxide 
nanoparticles suppressed DTH reactions
The effect of iron oxide nanoparticles on DTH reactions 
was firstly investigated by measuring the swelling of foot-
pads in mice sensitized and challenged with ovalbumin. 
Ovalbumin challenge markedly increased the thickness of 
footpads in ovalbumin-sensitized mice compared to the 
nonsensitized group (Figure 2A), signifying a success-
ful induction of DTH. Iron oxide nanoparticles (0.6 and 
10 mg iron/kg) showed a significant suppressive effect 
on footpad swelling, in which the inhibitory magnitude 
of the two doses was comparable, whereas the low dose 
(0.2 mg iron/kg) was ineffective (Figure 2A). Histological 
examination using hematoxylin and eosin staining showed 
a marked infiltration of mononuclear cells in subcutaneous 
tissues of the footpads in the untreated ovalbumin-sensitized 
and vehicle-treated groups, which appeared to be dimin-
ished by iron oxide nanoparticle administration (0.6 and 
10 mg iron/kg; Figure 2B). To more specifically character-
ize the types of inflammatory cells influenced by iron oxide 
nanoparticles, the number of total T cells (CD3+), regulatory 
T cells (Foxp3+), and macrophages (F4/80+) and the expres-
sion of IFN-γ, IL-6, and TNF-α in the footpads was measured 
by immunohistochemical staining. The signal of IFN-γ, IL-6, 
and TNF-α was primarily detected perivascularly in the 
dermis layer, which was markedly suppressed by iron oxide 
nanoparticle treatment (0.6 and 10 mg iron/kg; Figure 3A–C 
and Table 1). Furthermore, the number of CD3+ and F4/80+ 
cells was significantly suppressed in mice administered with 
iron oxide nanoparticles (0.6 and 10 mg iron/kg) compared 
to the vehicle-treated control (Table 1). In contrast, the 
infiltration of Foxp3+ cells was not altered by iron oxide 
nanoparticles (Table 1).
Differential effects of iron oxide 
nanoparticles on T cell functionality
Cytokines expressed by T cells play an essential role dictating 
antigen-specific immune reactions, including humoral and 
cell-mediated immunity. To investigate the influence of iron 
oxide nanoparticles on the functionality of T cells in DTH 
reactions, splenocytes harvested from nonsensitized and 
ovalbumin-sensitized mice were restimulated with ovalbumin 
(50 µg/mL) in culture for 72 hours to induce the production of 
antigen-specific cytokines. As shown in Figure 4, both IFN-γ 
and IL-4 were markedly induced by ovalbumin stimulation in 
the ovalbumin-sensitized groups compared to the nonsensitized 
group, demonstrating a successful induction of antigen-
specific T cell reactivity. Consistent with the reduced footpad 
swelling, iron oxide nanoparticles (0.6 and 10 mg iron/kg) 
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Figure 2 Inhibition by iron oxide nanoparticle administration of the footpad swelling 
and  inflammatory  cell  infiltration  associated  with  delayed-type  hypersensitivity. 
BALB/c  mice  were  treated  as  the  protocol  depicted  in  Figure  1.  Delayed-type 
hypersensitivity reactions in the footpad were induced by a subcutaneous ovalbumin 
challenge. (A) The thickness of footpads was measured before and 24 hours after 
the ovalbumin challenge. (B) The tissue sections were stained with hematoxylin 
and eosin (original magnification, ×200). Boxes show subcutaneous regions with 
heavy  infiltration  of  mononuclear  cells  in  the  untreated  ovalbumin-sensitized 
group and vehicle-treated group, which appears to be diminished in the iron oxide 
nanoparticle-treated (0.6 and 10 mg/kg) groups. 
Notes:  The  data  are  expressed  as  the  mean  ±  standard  error  of  six  to  eight 
samples per group. *P , 0.05 compared to the vehicle-treated group. Results are 
representative of three independent experiments. 
Abbreviations: Fe, iron; NS, nonsensitized group; OVA, untreated ovalbumin-
sensitized and challenged group; VH, vehicle-treated plus ovalbumin-sensitized and 
challenged group.
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demonstrated a suppressive effect on the production of IFN-γ 
(Figure 4A). By contrast, administration of iron oxide nano-
particles (0.6 and 10 mg iron/kg) enhanced the production of 
IL-4 (Figure 4B). As the expression of cytokines was influ-
enced by iron oxide nanoparticle treatment, the viability of 
ovalbumin-stimulated splenocytes was further examined. The 
results from the methylthiazol tetrazolium assays showed that 
the viability of splenocytes was unaltered in mice administered 
with iron oxide nanoparticles (Figure 5).
Effects of iron oxide nanoparticles 
on phagocytic activity of CD11b+ 
splenocytes
To further examine the influence of iron oxide nanoparticles 
on the functionality of macrophages, the phagocytic activ-
ity of splenic CD11b+ cells was examined. The percentage 
of splenic CD11b+ cells engulfing the fluorescent probe 
pHrodo was significantly attenuated in mice administered 
with iron oxide nanoparticles (0.6 and 10 mg iron/kg; 
  Figure 6A). Representative histograms of the pHrodo uptake 
by splenic CD11b+ cells in the vehicle-treated and iron oxide 
nanoparticle-treated (10 mg iron/kg) groups are illustrated 
in Figure 6B.
Discussion
Although iron oxide nanoparticles have been reported to 
affect the functionality of T cells and antigen-presenting 
cells,12–16,18,19,23,24 evidence pertaining to their effects on Th1 
cell-mediated immunity in vivo remains mostly unknown. 
It was previously reported that systemic administration of 
ovalbumin-sensitized mice with iron oxide nanoparticles 
suppresses, the serum production of ovalbumin-specific 
immunoglobulin G1 and immunoglobulin G2a, and the 
expression of both IFN-γ and IL-4 by splenocytes.19 More-
over, a direct exposure of ovalbumin-primed splenocytes 
to iron oxide nanoparticles results in a reduced production 
of IFN-γ, but not IL-4.18 Because IFN-γ is a key cytokine 
expressed by Th1 cells, these results suggest that Th1 cells 
are potentially a more sensitive target to iron oxide nanopar-
ticles compared to Th2 cells. It was therefore hypothesized 
that iron oxide nanoparticles may inhibit the DTH reactions 
in which Th1 cells play a central role in the elicitation of 
antigen-specific immune responses. This hypothesis was sub-
stantiated by the results in the present study, which show that 
the footpad swelling was suppressed by a single intravenous 
administration of iron oxide nanoparticles. Concordantly, the 
infiltration of T cells and the expression of IFN-γ in footpads 
were attenuated by iron oxide nanoparticle treatment.
A
B
NS OVA
VH
0.6 mg Fe/kg 10 mg Fe/kg
0.2 mg Fe/kg
C
NS OVA
VH
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0.2 mg Fe/kg
Figure 3 Iron oxide nanoparticles inhibited the expression of interferon-γ and tumor 
necrosis factor-α in footpads. (A) Representative light micrograph of interferon-
γ-stained footpad sections is shown (original magnification, ×200). The box shows 
subcutaneous regions with interferon-γ signals in the untreated ovalbumin-sensitized 
group. Representative light micrographs of (B) interferon-γ-stained and (C) tumor 
necrosis factor-α-stained footpad sections are shown (original magnification, ×400). 
Notes: Arrows indicate positive cells. Quantified data are presented in Table 1. 
Abbreviations:  Fe,  iron;  NS,  nonsensitized  group;  OVA,  untreated  ovalbumin-
sensitized and challenged group; VH, vehicle-treated plus ovalbumin-sensitized and 
challenged group.
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It was previously reported that high doses (30 and 
60 mg iron/kg) of iron oxide nanoparticles cause an overall 
suppressive effect on the expression of both Th1 and Th2 
cytokines by splenocytes of ovalbumin-sensitized mice, 
whereas a low dose (10 mg iron/kg) affects the produc-
tion of IFN-γ, but not IL-4.19 Hence, 10 mg of iron/kg was 
employed in the present study, and the results confirmed the 
sensitivity of IFN-γ to the dose of iron oxide nanoparticles. 
The study further extended to a lower dose (0.6 mg iron/kg) 
in mice with DTH, which enhanced the production of IL-4 
(Figure 4). These results suggest that the dose of iron oxide 
nanoparticles plays a critical role dictating the effects of 
iron oxide nanoparticles on T cells, in which doses #10 mg 
iron/kg may shift the Th1/Th2 immunobalance toward the 
Th2-dominant direction in ovalbumin-sensitized mice. 
The potential impact of iron oxide nanoparticles on Th2 
cell-mediated immunity, such as allergy, warrants further 
investigations using appropriate models.
The recommended doses of iron oxide nanoparticles 
as contrast agents to enhance the signal of magnetic reso-
nance imaging are 25.2 mg iron (0.9 mL of Resovist) 
and 39.2 mg iron (1.4 mL) for adults weighing ,60 kg 
and $60 kg, respectively.25,26 Hence, the clinical dose 
range of Resovist is greater than 0.42 mg iron/kg for 
adults weighing ,60 kg and less than 0.65 mg iron/kg for 
adults weighing $60 kg. In the present study, the dose of 
0.6 mg iron/kg was effective to curb DTH reactions, dem-
onstrating the impact of iron oxide nanoparticles at a clini-
cally relevant dose on Th1 cell-mediated immunity.
Previous studies reported that iron oxide nanoparticles 
activated macrophages and induced a proinflammatory 
effect when administered locally to the airways.15,27 In 
contrast, the present study showed a suppressive effect 
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Figure  4  Differential  effects  of  iron  oxide  nanoparticles  on  the  production  of 
antigen-specific interferon-γ and interleukin-4 by splenocytes. Splenocytes isolated 
from each group of mice were cultured in the presence of ovalbumin (50 µg/mL) for 
72 hours, and the supernatants were collected for measurement of (A) interferon-γ 
and (B) interleukin-4 by enzyme-linked immunosorbent assay. 
Note: Data are expressed as the mean ± standard error of six samples pooled from 
two experiments; *P , 0.05 compared to the vehicle-treated group.
Abbreviations: Fe, iron; NS, nonsensitized group; OVA, untreated ovalbumin-
sensitized and challenged group; VH, vehicle-treated plus ovalbumin-sensitized and 
challenged group.
Table 1 Immunohistochemical staining of CD3+, F4/80+, Foxp3, interferon-γ, interleukin-6, and tumor necrosis factor-α+ cells in the 
footpads of ovalbumin-sensitized and challenged mice
Number of positive cells
Iron oxide nanoparticles (mg iron/kg)
NS OVA VH 0.2 0.6 10
CD3+ 16 ± 3 52 ± 9 67 ± 11 65 ± 4 25 ± 3* 21 ± 4*
F4/80+ 3 ± 1 39 ± 4 33 ± 4 30 ± 5 10 ± 3* 8 ± 2*
Foxp3+ 2 ± 1 5 ± 1 5 ± 1 5 ± 1 4 ± 1 4 ± 1
IFN-γ+ 4 ± 1 24 ± 5 24 ± 5 18 ± 3 6 ± 2* 5 ± 1*
IL-6+ 5 ± 1 17 ± 3 18 ± 3 13 ± 2 6 ± 2* 7 ± 1*
TNF-α+ 10 ± 2 56 ± 11 62 ± 16 50 ± 16 10 ± 2* 7 ± 2*
Notes: The footpad sections were stained with antibodies against CD3, F4/80, Foxp3, interferon-γ, interleukin-6, and tumor necrosis factor-α as described in the materials 
and methods. The number of positively stained cells was counted manually. Data are expressed as the mean ± standard error of six to eight footpads per group. Results are 
representative of three independent experiments. *P , 0.05 compared to the vehicle-treated group.
Abbreviations: IFN, interferon; IL, interleukin; NS, nonsensitized group; OVA, untreated ovalbumin-sensitized and challenged group; VH, vehicle-treated and ovalbumin-
sensitized and challenged group.
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Figure  5  Effect  of  iron  oxide  nanoparticles  on  the  viability  of  splenocytes. 
Splenocytes isolated from each group of mice were cultured in the presence of 
ovalbumin (50 µg/mL) for 72 hours. The viability of splenocytes was determined by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide assay. 
Notes: Data are expressed as the mean ± standard error of quadruplicate cultures. 
Results are representative of three independent experiments.  
Abbreviations:  Fe,  iron;  NS,  nonsensitized  group;  OD,  optical  density; 
OVA  (key),  ovalbumin;  OVA  (X-axis),  untreated  ovalbumin-sensitized  and 
challenged group; VH, vehicle-treated plus ovalbumin-sensitized and challenged   
group.
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Figure 6 Iron oxide nanoparticles suppressed the phagocytic activity of splenic CD11b+ 
cells. (A) CD11b+ cells from the spleen were isolated using anti-CD11b magnetic 
beads. The phagocytic activity of CD11b+ cells was measured by flow cytometry 
using  pH-sensitive  pHrodo®  Escherichia  coli  BioParticles™  conjugate  (Invitrogen 
Life Technologies, Carlsbad, CA) as described in the materials and methods. (B) 
Representative histograms of the uptake of pHrodo by splenic CD11b+ cells in vehicle-
treated and iron oxide nanoparticle-treated (10 mg/kg) groups are illustrated. 
Notes: Data are expressed as the mean ± standard error of triplicate samples per 
group; *P , 0.05 compared to the vehicle-treated group. Results are representative 
of three independent experiments. 
Abbreviations: Fe, iron; NS, nonsensitized group; OVA, untreated ovalbumin-
sensitized and challenged group; VH, vehicle-treated plus ovalbumin-sensitized and 
challenged group.
on the functionality of both macrophages and Th1 cells 
by systemically administered iron oxide nanoparticles. 
These results suggest that the way of administration may 
be a critical factor influencing the immunomodulatory 
effects of iron oxide nanoparticles. In addition, the nature 
of immune responses could be another key factor in that 
no antigen sensitization was applied in the airway studies, 
whereas the DTH reactions were antigen-specific. It is well 
established that both T cells and macrophages are involved 
in the pathophysiology of DTH, in which IFN-γ expressed 
by antigen-activated Th1 cells stimulates macrophages that 
subsequently trigger inflammatory responses.20,28 In light of 
this premise, it was speculated that the downregulated activi-
ties of macrophages in iron oxide nanoparticle-treated mice 
could be due to the suppressive effect of the nanoparticles 
on T cells. Obviously, the potential impact of iron oxide 
nanoparticles on the functionality of macrophages may be 
dictated by different routes of exposure. As demonstrated 
in the present study for the scenario of systemic exposure, 
iron oxide nanoparticles suppress the function of both mac-
rophages and T cells in response to antigen stimulation. As 
Th cells play an essential role in the regulation of different 
arms of antigen-specific immunity, addressing the impact 
on the functionality of Th cells would be crucial for assess-
ing the nanotoxicology of iron oxide nanoparticles when 
systemic exposure is concerned.
In addition to the route of exposure, antigen sensitiza-
tion and challenge is another potential factor influencing 
the different effects induced by systemic and intratracheal 
administrations of iron oxide nanoparticles.
The observed inhibition of DTH responses by iron 
oxide nanoparticles is in line with a recent report showing 
a similar suppressive effect by fullerene nanoparticles.29 It 
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is noticed that both studies employed intravenous injection 
for nanoparticle administration. However, the underlying 
mechanisms are quite different. The study of fullerene 
nanoparticles showed an enhanced number of regulatory T 
cells and an attenuated expression of the proinflammatory 
cyto  kines IL-6 and IL-17, whereas the expression of TNF-α 
was paradoxically enhanced.29 Hence, the mechanism of 
action for fullerene nanoparticles was attributed to an 
upregulation of the regulatory immunity. By contrast, the 
present data showed a concordant attenuation of the func-
tionality of both Th1 cells and their downstream effector 
cells, namely macrophages, whereas the number of Foxp3+ 
cells in footpads was unaltered. The suppression of mac-
rophage functions was further substantiated by the present 
data showing a significant attenuation of the expression of 
IL-6 and TNF-α in footpads and the phagocytic activity 
in splenic CD11b+ cells of iron oxide nanoparticle-treated 
mice. Collectively, despite different mechanisms of action, 
both fullerene and iron oxide nanoparticles elicit a simi-
lar suppressive effect on DTH, suggesting the potential 
health impact on Th1 immunity by systemic exposure of 
nanoparticles.
Conclusion
The present study demonstrated that a single administra-
tion of iron oxide nanoparticles at a clinically relevant 
dose attenuated DTH reactions. Iron oxide nanoparticles 
suppressed the systemic production of IFN-γ  – a Th1 sig-
nature cytokine – by splenocytes, as well as locally in the 
inflamed footpads. In addition to T cells, the functionality of 
macrophages associated with DTH was attenuated, includ-
ing the infiltration and expression of the proinflammatory 
cytokines IL-6 and TNF-α in the inflammatory site. These 
results provide critical insights into the health impact of 
iron oxide nanoparticles on cell-mediated immunity. The 
potential immunotoxicity of iron oxide nanoparticles war-
rants further investigation.
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